RESUMO
INTRODUCTION: The impact of ustekinumab (UST) therapy on surgical complications in patients with Crohn's disease (CD) remains controversial. The aim of this meta-analysis is to explore the link between these two. METHODS: Databases (PubMed, Web of Science, Cochrane, and Springer Link) were searched until April 2022. Studies of CD patients who received UST and no UST prior to surgery (including no biological therapy, anti-tumor necrosis factor-α [anti-TNF-α] agent, and vedolizumab [VDZ]) were included. Primary outcomes included overall complications, infectious complications, and noninfectious complications. RESULTS: Nine studies totaling 3,225 CD patients were enrolled; 332 patients received UST treatment. There was no evidence of difference in the overall complications (odds ratio [OR] = 0.84, p = 0.37, 95% confidence interval [CI] = [0.57-1.23], I2 = 40%) between CD patients who had UST treatment preoperatively and those who had no UST treatment. There was no evidence of a difference in infectious complications (OR = 1.15, p = 0.35, 95% CI = [0.86-1.53], I2 = 2%). Additionally, there was no significant evidence of difference between these groups in terms of noninfectious complications and death. Specifically, there was no evidence of difference in overall complications, infection complications (including wound complications, sepsis, abscess, and anastomotic leakage), and noninfection complications (ileus, readmission, and return to operation), compared with no biological therapy and anti-TNF-α agents. At the same time, no significant evidence of difference was discovered in the comparison of preoperative UST and VDZ therapy in terms of overall complications, infectious complications (sepsis and abscess), and noninfectious complications (intestinal obstruction, readmission, and recovery surgery). CONCLUSION: In general, compared with other biological agents, preoperative use of UST in the treatment of CD patients is usually safe and does not increase surgical complications.
Assuntos
Doença de Crohn , Sepse , Humanos , Doença de Crohn/complicações , Doença de Crohn/tratamento farmacológico , Doença de Crohn/cirurgia , Ustekinumab/efeitos adversos , Inibidores do Fator de Necrose Tumoral , Abscesso/induzido quimicamente , Fator de Necrose Tumoral alfa , Estudos RetrospectivosRESUMO
BACKGROUND/AIM: Antiresorptive drugs (e.g., bisphosphonates, denosumab) are crucial in the treatment of oncological diseases. However, these antiresorptive drugs can cause medication-related osteonecrosis of the jaw (MRONJ). MRONJ is a challenging disease regarding the soft tissue defect treatment. There are various surgical reconstruction techniques. One of them is the nasolabial flap. CASE REPORT: The present case report describes a 76-year-old female suffering from MRONJ leading to a progressive abscess of the mandible as well as an intra/extraoral fistula with extent to the chin region. Surgical splitting of the abscess was performed immediately. In the further course, a surgical decortication of the mandible with soft tissue defect treatment using a mucoperiosteal flap was performed. Intraoperatively, the bone of the mandible showed severe necrotic defects in multiple locations. Therefore, a continuity resection of the mandible with an insertion of a reconstruction plate was performed. Postoperatively, however, there was a progressive wound dehiscence. Due to the persisting regression of the gingival mucosa, the soft tissue defect was treated with a caudally pedicled bilateral nasolabial flap. The further clinical follow-up showed no recurrence of MRONJ with a well-healed nasolabial flap. CONCLUSION: In addition to mucoperiosteal flaps and microvascular reconstructions, the nasolabial flap can be a sufficient surgical therapy for intraoral soft tissue defect reconstruction.
Assuntos
Osteonecrose da Arcada Osseodentária Associada a Difosfonatos , Conservadores da Densidade Óssea , Osteonecrose , Feminino , Humanos , Idoso , Conservadores da Densidade Óssea/efeitos adversos , Abscesso/induzido quimicamente , Abscesso/tratamento farmacológico , Retalhos Cirúrgicos , Difosfonatos , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/cirurgiaRESUMO
INTRODUCTION: Gonococcal infection of the penile raphe is rarely encountered in the clinical setting. The study aimed to understand the incidence, sites, clinical manifestations, and treatment of gonococcal infection of the penile raphe. METHODS: We enrolled men with gonococcal infection of the penile raphe and men with urethral gonorrhea from January 2010 to December 2021. All patients' demographic data and clinical characteristics were recorded. All patients were treated with ceftriaxone. Incision and drainage were performed in patients with non-ruptured abscesses. Nodules and sinus tract-like lesions that did not resolve after 1 month of treatment were excised. RESULTS: Among 2,736 men who presented with urethral gonorrhea from January 2010 to December 2021, 5 (0.18%) had accompanying gonococcal infection of the penile raphe. An additional two men presented with gonococcal infection of the penile raphe without urethritis. Thus, 7 (0.26%; confidence interval, 0.11-0.56%) of 2,738 men had urethral gonorrhea or gonococcal infection of the penile raphe confirmed both clinically and by laboratory testing. Lesions were present in the frenulum of the prepuce and at the median aspect, proximal end, distal end, and both the proximal and distal ends of the penile raphe. The lesions manifested as abscesses, ulcers, a nodule, and a nodule with a sinus-like lesion. All lesions exhibited tenderness. All seven patients were cured after treatment. CONCLUSION: Gonococcal infection of the penile raphe is a rare, atypical type of involvement of the male urogenital tract by Neisseria gonorrhoeae. It may be a local complication of urethral gonorrhea or an independent primary infection. The proximal end, distal end, and median aspect of the penile raphe can be infected by N. gonorrhoeae. Cutaneous lesions present as abscesses, ulcers, nodules, and sinus-like lesions. Ceftriaxone is effective, but sinus-like lesions require surgery.
Assuntos
Gonorreia , Humanos , Masculino , Gonorreia/complicações , Gonorreia/diagnóstico , Gonorreia/tratamento farmacológico , Ceftriaxona/uso terapêutico , Abscesso/induzido quimicamente , Abscesso/complicações , Abscesso/tratamento farmacológico , Úlcera , Neisseria gonorrhoeaeRESUMO
A tubo-ovarian abscess (TOA) is a common type of inflammatory lump in clinical practice. TOA is an important, life-threatening disease, and it has become more common in recent years, posing a major health risk to women. Broad-spectrum antimicrobial agents are necessary to cover the most likely pathogens because the pathogens that cause TOA are polymicrobial. However, the response rate of antibiotic treatment is about 70%, whereas one-third of patients have poor clinical consequences and they require drainage or surgery. Rising antimicrobial resistance serves as a significant reason for the unsatisfactory medical outcomes. It is important to study the antibiotic resistance mechanism of TOA pathogens in solving the problems of multi-drug resistant strains. This paper focuses on the most common pathogenic bacteria isolated from TOA specimens and discusses the emerging trends and epidemiology of resistant Escherichia coli, Bacteroides fragilis, and gram-positive anaerobic cocci. Besides that, new methods that aim to solve the antibiotic resistance of related pathogens are discussed, such as CRISPR, nanoparticles, bacteriophages, antimicrobial peptides, and pathogen-specific monoclonal antibodies. Through this review, we hope to reveal the current situation of antibiotic resistance of common TOA pathogens, relevant mechanisms, and possible antibacterial strategies, providing references for the clinical treatment of drug-resistant pathogens.
Assuntos
Abscesso , Infecções Bacterianas , Abscesso/induzido quimicamente , Abscesso/tratamento farmacológico , Abscesso/microbiologia , Antibacterianos/efeitos adversos , Bactérias , Infecções Bacterianas/tratamento farmacológico , Resistência Microbiana a Medicamentos , Feminino , HumanosRESUMO
PURPOSE: We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. It expands the known spectrum of complications of Crizotinib. METHODS: Clinical case report. RESULTS: Multiple aseptic and recurrent abscesses were observed in the liver, thoracic wall as well as in both kidneys in a 75-year-old female patient suffering from NSCLC who had been treated with Crizotinib for almost 2 years. After discontinuation of the treatment the abscesses dissolved spontaneously and did not reoccur. CONCLUSION: Aseptic abscesses under treatment with Crizotinib are not restricted to the kidneys as described before, but can also occur in other abdominal organs as the liver and even in the thoracic wall. We postulate that this finding may point to a yet unknown not tissue-dependent mechanism of action.
Assuntos
Abscesso/induzido quimicamente , Antineoplásicos/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Crizotinibe/efeitos adversos , Neoplasias Pulmonares/tratamento farmacológico , Idoso , Carcinoma Pulmonar de Células não Pequenas/genética , Feminino , Humanos , Neoplasias Pulmonares/genética , Proteínas de Fusão Oncogênica/genética , Inibidores de Proteínas Quinases/efeitos adversosRESUMO
PURPOSE: The purpose of this retrospective study is to evaluate the role of echo-color-Doppler (ECD) imaging in identifying a series of characteristics pursuant to aesthetic filling material such as their degree of absorbability and their potential complications which include their propensity to stimulate the formation of encapsulated foreign-body granulomas. In the latter case, ECD can be of aid by giving indication for surgical therapy. MATERIALS AND METHODS: Over a 4-year period, we studied 180 patients (60 â) who underwent an aesthetic medical/surgical treatment. We used ECD to evaluate the implant material, its thickness, the injection site, the integrity of dermal layers and the presence of any associated complications. RESULTS: In 97% (174/180) of our patients, we were able to identify the type of material used; furthermore, 57% of patients had a hyaluronic acid implant, 14% a lipofilling and 29% a non-absorbable filler (with 10% of silicone). In 6/180 (3%), we could not recognize the material used; 89% (161/180) of our patients presented post-injection complications; moreover, 67% showed peri-implant dermal-hypodermal thickening areas with adjacent lymphostasis, 6% displayed an abnormal implant site, and 17% showed inflammation with encapsulated foreign-body granulomas that required subsequent surgical excision. Biopsy samples were obtained from 37/180 patients (21%); among these, 31 patients had an ECD evidence of granuloma and on 6 patients we were not able to define the injected material. Histopathological examination identified 29 granulomas, 5 sterile abscesses and 3 chronic inflammations in the absence of granuloma. ECD showed an overall 78% diagnostic accuracy, with 90% sensitivity and 37% specificity in detecting filler granulomas. CONCLUSION: ECD is a low-cost technique that allows to identify filling materials and to assess the complications of an esthetic medical/surgical treatment.
Assuntos
Abscesso/induzido quimicamente , Abscesso/diagnóstico por imagem , Técnicas Cosméticas/efeitos adversos , Preenchedores Dérmicos/efeitos adversos , Granuloma de Corpo Estranho/induzido quimicamente , Granuloma de Corpo Estranho/diagnóstico por imagem , Ultrassonografia Doppler em Cores , Adulto , Biópsia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
Local corticosteroid injections are frequently used in the management of trigger finger. We present a case of a 56-year-old woman who developed an acute horseshoe abscess of the hand after injection of corticosteroid and local anaesthetic into the left thumb. This was managed successfully with intravenous antibiotics, operative intervention and early mobilisation. This case highlights the possible complications that can occur with such a minimally invasive procedure. The pathophysiology behind this condition is explained by communication between the radial and ulnar bursae. Knowledge of the anatomy of the hand and its variants is therefore essential to assist in diagnosis. Prompt clinical diagnosis and surgical management is required to avoid disastrous complications.
Assuntos
Abscesso/diagnóstico , Anestésicos Locais/efeitos adversos , Glucocorticoides/efeitos adversos , Mãos , Infecções Estafilocócicas/diagnóstico , Staphylococcus aureus , Dedo em Gatilho/tratamento farmacológico , Abscesso/induzido quimicamente , Abscesso/tratamento farmacológico , Anestésicos Locais/administração & dosagem , Antibacterianos/uso terapêutico , Diagnóstico Diferencial , Feminino , Glucocorticoides/administração & dosagem , Humanos , Injeções Intramusculares , Pessoa de Meia-Idade , Infecções Estafilocócicas/induzido quimicamente , Infecções Estafilocócicas/tratamento farmacológicoRESUMO
We present two 11-year-old girls with chronic recurrent multifocal osteomyelitis, treated with adalimumab. Both developed severe intracranial complications to sinusitis. Patient 1 had been treated with adalimumab for 15 months when she developed acute sinusitis complicated by an orbital abscess, forehead swelling, a subdural empyema and osteomyelitis of the frontal bone. She was treated with a rhinosurgical and neurosurgical approach with intravenous antibiotics.Patient 2 had been in adalimumab treatment for 10 weeks. Adalimumab was discontinued 8 weeks prior to developing subdural empyema and subcortical abscesses in combination with sinusitis. She was treated with endoscopic sinus surgery and intravenous antibiotics. Both patients had developed psoriasis and episodes of infection during treatment. They were non-septic and had low fever on presentation. None of the patients suffered any long-term neurological sequelae. The immunosuppressive treatment with adalimumab is considered to be the cause of the sinogenic intracranial complications in our cases.
Assuntos
Adalimumab/efeitos adversos , Anti-Inflamatórios/efeitos adversos , Encefalopatias/induzido quimicamente , Osteomielite/tratamento farmacológico , Sinusite/induzido quimicamente , Abscesso/induzido quimicamente , Doença Aguda , Abscesso Encefálico/induzido quimicamente , Criança , Empiema Subdural/induzido quimicamente , Feminino , Humanos , Doenças Orbitárias/induzido quimicamenteRESUMO
The aim of this study was to determine the role of nonsteroidal anti-inflammatory drugs (NSAID) injection on the severity of local infection and the effect on the progression of soft tissue infection (STI).The mouse model of STI with Group A streptococcus (GAS) was developed and treated with diclofenac sodium (DS) intramuscularly. Mice were divided into five groups: administered DS for 48 h before GAS (Group 1), GAS-DS and maintained DS for 48 h (Group 2), DS for 48 h (Group 3), GAS on zero time (Group 4), and control (Group 5). In vitro, a high concentration (40 mg/L) of DS inhibited GAS growth, whereas a lower concentration (0.4 mg/L) was not effective. Sepsis was observed in animals with DS and GAS inoculation (group 1 and 2). Group 4 had statistically significant higher bacterial load than groups 1 and 2. All groups had a higher inflammation rate than the control group. The median of TNF-alpha and mean IL-6 in the groups 1, 2, and 4 was significantly higher than those in the control group. Even if the animals that were treated with DS injection prior to the GAS inoculation had similar inflammation score, similar cytokine levels and low bacterial load in the tissue, they had a rather high rate of sepsis. In conclusion, DS injection prior to bacterial inoculation might predispose to bacteremia and sepsis.
Assuntos
Anti-Inflamatórios não Esteroides/toxicidade , Diclofenaco/toxicidade , Sepse/induzido quimicamente , Infecções dos Tecidos Moles/induzido quimicamente , Infecções Estreptocócicas/induzido quimicamente , Streptococcus pyogenes/patogenicidade , Abscesso/sangue , Abscesso/induzido quimicamente , Abscesso/microbiologia , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Bacteriemia/sangue , Bacteriemia/induzido quimicamente , Bacteriemia/microbiologia , Carga Bacteriana , Diclofenaco/administração & dosagem , Modelos Animais de Doenças , Feminino , Mediadores da Inflamação/sangue , Injeções Intramusculares , Interleucina-6/sangue , Camundongos Endogâmicos BALB C , Sepse/sangue , Sepse/microbiologia , Sepse/patologia , Infecções dos Tecidos Moles/sangue , Infecções dos Tecidos Moles/microbiologia , Infecções dos Tecidos Moles/patologia , Infecções Estreptocócicas/sangue , Infecções Estreptocócicas/microbiologia , Infecções Estreptocócicas/patologia , Fatores de Tempo , Fator de Necrose Tumoral alfa/sangueRESUMO
An 86-year-old Japanese man was diagnosed with stage IV lung adenocarcinoma. The patient was treated with crizotinib after echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement was detected from his pleural effusion. He subsequently developed abdominal pain and rebound tenderness in the right lower abdomen. Contrast-enhanced abdominal CT showed a low-density area in the abdominal cavity. The size of the abscess was decreased by drainage and the administration of antibiotics. Fistulography revealed a fistula from the rectum to the abscess, and a diagnosis of lower intestinal tract perforation with abscess formation was made. Crizotinib was discontinued and treatment with alectinib was initiated. The patient remains under treatment as an outpatient at our department without adverse effects.
Assuntos
Abscesso/induzido quimicamente , Adenocarcinoma/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Perfuração Intestinal/induzido quimicamente , Neoplasias Pulmonares/tratamento farmacológico , Inibidores de Proteínas Quinases/efeitos adversos , Pirazóis/efeitos adversos , Piridinas/efeitos adversos , Reto/fisiopatologia , Adenocarcinoma de Pulmão , Idoso de 80 Anos ou mais , Povo Asiático , Carcinoma Pulmonar de Células não Pequenas/patologia , Crizotinibe , Fístula/induzido quimicamente , Humanos , Masculino , Inibidores de Proteínas Quinases/uso terapêutico , Pirazóis/uso terapêutico , Piridinas/uso terapêutico , Resultado do TratamentoRESUMO
Central skull-base osteomyelitis (CSBO) is a rare life-threatening infection, usually resulting from medial spread of necrotising otitis externa. Here, we describe a case with no identifiable source of infection, causing a delay in diagnosis. An 80-year-old man with Crohn's disease treated with mesalazine presented with collapse and tonic-clonic seizure. Computed tomography and magnetic resonance imaging showed a nasopharyngeal mass that was initially thought to be a neoplasm. Awaiting formal biopsy, he represented with collapse and repeat imaging showed features of abscess formation. Review of previous scans revealed skull-base erosion and the diagnosis was revised to skull-base osteomyelitis. This is the first reported case of CSBO associated with mesalazine use, an aminosalicylate used in Crohn's disease. It is only the second reported case with abscess formation. We discuss the learning points in making a timely diagnosis and examine the potential association of factors such as mesalazine use and abscess formation in this case.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Doença de Crohn/tratamento farmacológico , Mesalamina/efeitos adversos , Osteomielite/induzido quimicamente , Abscesso/induzido quimicamente , Abscesso/diagnóstico , Idoso de 80 Anos ou mais , Doença de Crohn/complicações , Diagnóstico Tardio , Humanos , Biópsia Guiada por Imagem , Imageamento por Ressonância Magnética , Masculino , Neoplasias Nasofaríngeas/diagnóstico , Osteomielite/diagnóstico , Infecções por Pseudomonas/induzido quimicamente , Infecções por Pseudomonas/diagnóstico , Pseudomonas aeruginosa , Base do Crânio , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND: Hepatic inflammatory pseudotumor (IPT) is a rare disease which often mimics a malignant tumor and is therefore often misdiagnosed and surgically resected. Recently, a concept of IgG4-related diseases (IgG4-RD) has been proposed that is becoming widely recognized and includes IgG4-related hepatic IPT. Corticosteroids are widely accepted as the standard treatment. CASE PRESENTATION: A 72-year-old Japanese man, who had been followed for ten years after surgery and chemotherapy for treatment of hilar and lower bile duct cancers, developed intermittent fever and abdominal pain and visited this hospital. Blood examinations revealed an inflammatory reaction, worsened glucose intolerance, and an increased level of serum IgG4 (137 mg/dL). Computed tomography (CT) revealed a 5 cm-sized mass in hepatic segment 7. Because of his cancer history, not only was a benign mass suspected, but there was also the possibility of a recurrent biliary malignancy. Liver biopsy was performed and the histology met the criteria for IgG4-related IPT. Corticosteroid therapy was initiated and his symptoms quickly resolved. However, two months later, a repeat CT demonstrated that the hepatic mass had been replaced by an abscess. The abscess was initially refractory, despite tapering corticosteroid treatment, controlling diabetes by intensive insulin therapy, administration of antibiotics, and percutaneous abscess drainage. Finally, after six months, the condition resolved. CONCLUSION: The diagnosis of hepatic IPT is sometimes difficult. To differentiate it from a malignant tumor, histological examination is necessary. Although corticosteroids are recognized as the standard therapy, unexpected and critical complications can develop in cases of IgG4-related hepatic IPT.
Assuntos
Abscesso/induzido quimicamente , Corticosteroides/efeitos adversos , Granuloma de Células Plasmáticas/diagnóstico , Granuloma de Células Plasmáticas/tratamento farmacológico , Imunoglobulina G/sangue , Hepatopatias/diagnóstico , Hepatopatias/tratamento farmacológico , Abscesso/terapia , Corticosteroides/uso terapêutico , Idoso , Diagnóstico Diferencial , Granuloma de Células Plasmáticas/imunologia , Humanos , Hepatopatias/imunologia , MasculinoRESUMO
Since the 1990s, U.S. heroin consumers have been divided from the full range of available products: east of the Mississippi River, Colombian-sourced powder heroin (PH) dominates the market while, to the west, Mexican-sourced "black tar" (BTH) is the main heroin available. By conducting qualitative research in two exemplar cities, Philadelphia (PH) and San Francisco (BTH), we compare users' experiences of heroin source-types, markets, health consequences, and consumption preferences. The strict division of heroin markets may be changing with novel forms of powder heroin appearing in San Francisco. Our researchers and interviewees perceived vein loss stemming from the injection of heroin alone to be a particular problem of BTH while, among the Philadelphia sample, those who avoided the temptations of nearby cocaine sales displayed healthier injecting sites and reported few vein problems. Abscesses were common across both sites, the Philadelphia sample generally blaming missing a vein when injecting cocaine and the San Francisco group finding several explanations, including the properties of BTH. Consumption preferences revealed a "connoisseurship of potency," with knowledge amassed and deployed to obtain the strongest heroin available. We discuss the reasons that their tastes take this narrow form and its relationship to the structural constraints of the heroin market.
Assuntos
Dependência de Heroína/epidemiologia , Heroína/efeitos adversos , Abuso de Substâncias por Via Intravenosa/epidemiologia , Abscesso/induzido quimicamente , Abscesso/epidemiologia , Adulto , Feminino , Heroína/química , Dependência de Heroína/complicações , Humanos , Entrevistas como Assunto , Masculino , Philadelphia/epidemiologia , São Francisco/epidemiologia , Abuso de Substâncias por Via Intravenosa/complicações , Doenças Vasculares/induzido quimicamente , Doenças Vasculares/epidemiologia , Adulto JovemRESUMO
Intravesical bacillus Calmette-Guerin (BCG) was a common treatment for non-muscle invasive urothelial carcinoma of the bladder. The complication of prostatic abscess was rare. We reported a case of tuberculous prostatic abscess after BCG therapy. A 65-year-old man was diagnosed as bladder cancer and accepted transurethral resection of bladder tumor (TURBT) treatment. He received a 6-week induction course without any infection complication. Following the second BCG maintenance instillation, he complained of fever and dysuria. Transrectal ultrasound (TRUS) demonstrated a well-defined complex mass in the right lobe of his prostate. The diagnosis of tuberculous prostatic abscess was considered after excluding other bacterial infection. The patient was treated with an anti-tuberculous regimen of isoniazid, rifampicin, and ethambutol. The symptoms were relieved after 4 weeks of anti-tuberculous therapy. Because of the good response to the medicine, no further aspiration or drainage of prostatic abscess was carried out. The anti-tuberculous therapy had to be stopped for serious drug induced liver injury after 6 weeks of anti-tuberculous therapy. Eight weeks later of stopping anti-tuberculous therapy, the follow-up TRUS showed the disappearance of the prostatic abscess and the test of his liver function was normal. Considering the virulence of BCG is weaker than that of common tuberclebacillus, the shorter course of anti-tuberculous therapy maybe an alternative choice, and surgical drainage is not always necessary.
Assuntos
Abscesso/induzido quimicamente , Administração Intravesical , Vacina BCG/efeitos adversos , Imunoterapia/efeitos adversos , Doenças Prostáticas/induzido quimicamente , Tuberculose/diagnóstico , Abscesso/diagnóstico , Idoso , Antineoplásicos , Carcinoma in Situ , Drenagem , Humanos , Masculino , Doenças Prostáticas/diagnóstico , Neoplasias da Bexiga Urinária/cirurgiaRESUMO
BACKGROUND: A review of 242 facial treatments, in 86 different patients, with polyacrylamide gel (PAAG) was carried out by the author between 2003 and 2013. OBJECTIVES: To evaluate by retrospective study the long-term outcomes of PAAG filling for facial contouring. To quantify adverse events and patient comfort in prior mixing 0.3 mL of 2% lidocaine/1 mL PAAG and decanting into a smaller volume syringe. METHOD: Review of clinical records combined with a patient survey. COMPLICATIONS: 11 of 166 (6.6%) lip body infections; 1 of 202 (0.5%) in other sites. Addition of 2% lidocaine (55 treatments/28 patients) reduced lip body infections (8.7% to 5.7%, P < 0.05%) and mean pain score (8/10 to 2/10). No patients sustained any long-term side effects and all (even those infected) were eventually satisfied. Seven lip asymmetries, after infected PAAG drainage, were corrected with further PAAG, showing adverse events to be contamination rather than immune reaction. CONCLUSION: Facial usage of PAAG with lidocaine results in high levels of patient satisfaction and low incidence of side effects (0.5%) except in the lip body (6.6%). Potential users, fearful of complications, may more readily use this cost-effective and long-lasting dermal filler if they avoid injection of the lip body.
Assuntos
Resinas Acrílicas/administração & dosagem , Técnicas Cosméticas/efeitos adversos , Lábio , Satisfação do Paciente , Abscesso/induzido quimicamente , Adulto , Anestésicos Locais/uso terapêutico , Antibacterianos/uso terapêutico , Géis , Granuloma/induzido quimicamente , Humanos , Injeções , Lidocaína/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do TratamentoRESUMO
The use of hyaluronic acid fillers for treatment of rhytides (wrinkles) is widespread in aesthetic dermatology and is considered a safe procedure; however, complications can occur especially if the injections are carried out by an inexperienced person and/or with a lack of anatomical knowledge. The two cases presented here exemplify this problem. In conclusion, both cases demonstrate complications after uncritical injection of hyaluronic acid fillers into "risk" or "expert" regions. While the patients in these two cases recovered completely, the injection of filler substances can also lead to the risk of potentially permanent side effects, such as granuloma, necrosis with scar tissue formation and even blindness. The frequency and severity of complications often show a direct correlation with the qualification or expertise of the person treating and hence injection treatments should be performed solely by physicians.
Assuntos
Abscesso/induzido quimicamente , Toxidermias/etiologia , Dermatoses Faciais/induzido quimicamente , Ácido Hialurônico/efeitos adversos , Viscossuplementos/efeitos adversos , Abscesso/diagnóstico , Abscesso/terapia , Toxidermias/diagnóstico , Toxidermias/terapia , Dermatoses Faciais/terapia , Feminino , Humanos , Ácido Hialurônico/administração & dosagem , Injeções Intradérmicas , Pessoa de Meia-Idade , Envelhecimento da Pele/efeitos dos fármacos , Viscossuplementos/administração & dosagemRESUMO
Injection of liquid silicone was performed illicitly in the 1950s to 1960s and was subsequently prohibited. Many complications arise from silicone injection, and liquid silicone migration is a complication that has not been widely reported. The 55-year-old woman was admitted with a palpable mass on her neck; her symptom started 2 weeks ago. Two years previously, she had received bilateral cosmetic silicone fluid injection in the multiple regions of her face. On physical examination, a 6 × 8-cm palpable mass was seen on anterolateral aspect of the right sternocleidomastoid muscle. On enhanced facial computed tomography, multiple abscesses were in the right malar, cheek, and preauricular region with abscess tract sequelae. The author prescribed cephalosporin intravenous antibiotics and performed 2 cm of incision line on the lower one-third neck with local anesthesia, and then drain tube was applied. After 5 days, mass on the neck was not palpated, and right buccal swelling was significantly diminished in size and reflected the resolution of the surrounding inflammatory reaction. Bacterial culture reported growth of some gram-negative rods, Burkholderia gladioli. All injectable dermal fillers can cause complications. Immediate reactions are transient and can include edema, erythema, nodularity, and pain. Late averse events also include immunologic phenomena such as late-onset allergy and nonallergic foreign body granuloma, autoimmune responses, or both. So in this case, the author guessed that silicone fluid causes abscess and then pseudocyst formation on the neck. The key to an accurate diagnosis is asking the patient specifically about his/her history of receiving cosmetic filler injections.
Assuntos
Técnicas Cosméticas/efeitos adversos , Cistos/induzido quimicamente , Géis de Silicone/efeitos adversos , Abscesso/induzido quimicamente , Bochecha/cirurgia , Feminino , Humanos , Injeções/efeitos adversos , Pessoa de Meia-Idade , PescoçoRESUMO
OBJECTIVE: To evaluate factors influencing the onset and type of adverse events in patients injected with permanent fillers in the face and to propose a therapeutic strategy for these complications. METHODS: A prospectively attained series of 85 patients with delayed-onset complications after facial injection with permanent fillers underwent clinical follow-up and treatment of the complications. RESULTS: Lag times until onset and type of delayed-onset complication varied according to filler material. In 28% (n = 24) of the cases, patients reported the onset of complications after dental procedures, additional injections with fillers, or other invasive treatments in the facial area. Forty-eight (57%) patients required invasive treatment. Abscess formation was significantly more frequent in patients with human immunodeficiency virus infection and facial lipoatrophy (p = .001). CONCLUSION: The intrinsic characteristics of the injected filler and the immune status of the patient play important roles in the diversity of time of onset and type of delayed-onset adverse events observed. It seems that invasive facial or oral procedures in the vicinity of filler depots can provoke such complications. We propose a strategy for treating these complications and advise great caution when using permanent filling agents.
Assuntos
Abscesso/induzido quimicamente , Tecido Adiposo/patologia , Técnicas Cosméticas/efeitos adversos , Infecções por HIV/tratamento farmacológico , Abscesso/microbiologia , Abscesso/cirurgia , Acrilatos/efeitos adversos , Resinas Acrílicas/efeitos adversos , Adulto , Idoso , Antirretrovirais/efeitos adversos , Atrofia/induzido quimicamente , Atrofia/tratamento farmacológico , Colágeno/efeitos adversos , Dimetilpolisiloxanos/efeitos adversos , Face , Feminino , Humanos , Ácido Hialurônico/efeitos adversos , Hidrogéis/efeitos adversos , Inflamação/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Polimetil Metacrilato/efeitos adversos , Estudos Prospectivos , Rejuvenescimento , Fatores de TempoRESUMO
BACKGROUND: Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. Interleukin 17 (IL-17) is thought to be a key inflammatory cytokine in the development of ankylosing spondylitis, the prototypical form of spondyloarthritis. We assessed the efficacy and safety of the anti-IL-17A monoclonal antibody secukinumab in treating patients with active ankylosing spondylitis. METHODS: We did a randomised double-blind proof-of-concept study at eight centres in Europe (four in Germany, two in the Netherlands, and two in the UK). Patients aged 18-65 years were randomly assigned (in a 4:1 ratio) to either intravenous secukinumab (2×10 mg/kg) or placebo, given 3 weeks apart. Randomisation was done with a computer-generated block randomisation list without a stratification process. The primary efficacy endpoint was the percentage of patients with a 20% response according to the Assessment of SpondyloArthritis international Society criteria for improvement (ASAS20) at week 6 (Bayesian analysis). Safety was assessed up to week 28. This study is registered with ClinicalTrials.gov, number NCT00809159. FINDINGS: 37 patients with moderate-to-severe ankylosing spondylitis were screened, and 30 were randomly assigned to receive either intravenous secukinumab (n=24) or placebo (n=6). The final efficacy analysis included 23 patients receiving secukinumab and six patients receiving placebo, and the safety analysis included all 30 patients. At week 6, ASAS20 response estimates were 59% on secukinumab versus 24% on placebo (99·8% probability that secukinumab is superior to placebo). One serious adverse event (subcutaneous abscess caused by Staphylococcus aureus) occurred in the secukinumab-treated group. INTERPRETATION: Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated. It is the first targeted therapy that we know of that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial. FUNDING: Novartis.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Antirreumáticos/administração & dosagem , Espondilite Anquilosante/tratamento farmacológico , Abscesso/induzido quimicamente , Adolescente , Adulto , Idoso , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Humanizados , Antirreumáticos/efeitos adversos , Biomarcadores/metabolismo , Método Duplo-Cego , Feminino , Humanos , Infusões Intravenosas , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Espondilite Anquilosante/complicações , Infecções Cutâneas Estafilocócicas/induzido quimicamente , Staphylococcus aureus , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: Corticosteroid are among the most commonly used medications for a wide range of inflammatory, autoimmune and neoplastic disorders. Therefore, it is important for the physician to be aware of their side effects, in relation to different forms and delivery, that occur more often with oral therapy. METHODS: A 33-year old professional drummer had been suffering from bilateral tenosynovitis of the wrists for three months. In order to accelerate the recovery and play drums again, he self-injected supra-therapeutic doses of triamcinolone acetonide (a total of injected drug > 2,400 mg was calculated) in his right gluteus. RESULTS: The intramuscular overuse of triamcinolone acetonide caused Cushing syndrome associated with a giant sterile abscess that involved the right gluteal muscles and the adjacent subcutaneous tissue. CONCLUSION: A large intramuscular sterile abscess can be a side effect of supra-therapeutic intramuscular triamcinolone dose and this should be explained to the patient prior to initiation of treatment with triamcinolone.